IMPL - Impel NeuroPharma, Inc. Stock Price, Fair Value and News

$0.02+0.01 (+100.00%)

Market Closed

IMPL Stock Valuation Analysis

Valuation

Max Portfolio %

IMPL Price Action

IMPL RSI Chart

IMPL Stock Valuation Analysis

Valuation

Max Portfolio %

IMPL Valuation

IMPL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

IMPL Fundamentals

IMPL Revenue

IMPL Earnings

IMPL Profitability

IMPL Investor Care

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	15.3M	19.0M	21.0M	0
2022	3.7M	6.7M	9.7M	12.7M
2021	0	0	0	668.0K

Get all data in R, Python etc through our Historical Stock Data APIs

About Impel NeuroPharma, Inc.

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.

CEO	Mr. Adrian Adams
WEBSITE	https://impelpharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	160